Kate Broderick, SVP of research and development at INOVIO and one of In Vivo’s 2021 rising leaders, is hopeful that greater collaboration will be the lasting effect of COVID-19.
Back To Rising Leaders Gallery
In her role as INOVIO Pharmaceuticals, Inc.’s senior vice president of research and development, Kate Broderick, an accomplished scientist...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.
